ABSTRACT: Reduced cerebral blood flow (CBF) in the temporoparietal region and gray matter volumes (GMVs) in the temporal lobe were previously reported in patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). However, the temporal relationship between reductions in CBF and GMVs requires further investigation. This study sought to determine if reduced CBF is associated with reduced GMVs, or vice versa. Data came from 148 volunteers of the Cardiovascular Health Study Cognition Study (CHS-CS), including 58 normal controls (NC), 50 MCI, and 40 AD who had perfusion and structural MRIs during 2002-2003 (Time 2). Sixty-three of the 148 volunteers had follow-up perfusion and structural MRIs (Time 3). Forty out of the 63 volunteers received prior structural MRIs during 1997-1999 (Time 1). The relationships between GMVs and subsequent CBF changes, and between CBF and subsequent GMV changes were investigated. At Time 2, we observed smaller GMVs (p<0.05) in the temporal pole region in AD compared to NC and MCI. We also found associations between: (1) temporal pole GMVs at Time 2 and subsequent declines in CBF in this region (p=0.0014) and in the temporoparietal region (p=0.0032); (2) hippocampal GMVs at Time 2 and subsequent declines in CBF in the temporoparietal region (p=0.012); and (3) temporal pole CBF at Time 2 and subsequent changes in GMV in this region (p = 0.011). Therefore, hypoperfusion in the temporal pole may be an early event driving its atrophy. Perfusion declines in the temporoparietal and temporal pole follow atrophy in this temporal pole region.

Key words: Alzheimer's disease, cerebral blood flow, arterial spin labeling, structural magnetic resonance imaging, gray matter volume

INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disease with progressive cognitive impairment, characterized by loss of neurons, plaques of insoluble amyloid-β (Aβ) and neurofibrillary tangles (NFTs) of phosphorylated microtubule-associated protein tau (P-tau) [1]. AD is associated with diminished cerebral blood flow (CBF) [2-
and gray matter volume (GMV) [5-7]. Declines in CBF were related to the decline of cognitive function and may precede the appearance of the clinical syndrome by many years [8]. The most consistent finding in the literature for mild cognitive impairment (MCI) and AD is decreased CBF and metabolism in the temporoparietal region at the early stage based on single photon emission computed tomography (SPECT), perfusion MRI, and positron emission tomography (PET) [9-12]. However, gray matter atrophy in the medial temporal lobe (MTL) [13-15], including the hippocampus and entorhinal cortex, was predominantly reported. Dissociated regional patterns of CBF and GMV have been observed in these cohorts [13, 16]. Indeed, it has been debated whether decreased CBF precedes brain atrophy because of a pathological reduction in blood supply (such as small vessel diseases) or follows brain atrophy that induces reduced metabolic demand from neurodegeneration in AD.

One hypothesis proposed that hippocampal atrophy occurs earlier than hypoperfusion in the temporoparietal region [17]. Other studies proposed and supported that vascular damage and reduced perfusion in the parietal association cortex leads to the initiation and exacerbation of AD pathology in MTL [18, 19]. One recent cross-sectional study demonstrated significant association of MTL volumes and CBF values in the typically reduced-perfusion regions of AD, including the angular gyrus/temporoparietal gyrus, precuneus, posterior cingulate, and middle frontal cortex [20]. However, longitudinal studies are preferable for determining the temporal relationship between temporoparietal hypoperfusion and MTL atrophy.

This study took advantage of the longitudinal design of the Cardiovascular Health Study (CHS) Cognition Study (CHS-CS). CBF maps and GMV maps were derived from noninvasive arterial spin labeling (ASL) MRI and T1-weighted structural MRI, respectively. Voxel-based GMV maps were compared among normal cognitive (NC) control, MCI, and AD subjects. The AD-associated atrophic clusters in the voxel-based GMV comparisons were considered as the atrophy regions of interest (ROIs). We hypothesized that the AD-associated atrophy ROIs are located in MTL. The AD-associated CBF ROIs were derived previously from voxel-based CBF comparisons among NC, MCI, and AD subjects [21]. Our study focused on two ROIs: one AD-associated CBF ROI (the temporoparietal region) and one AD-associated atrophy ROI. We investigated whether the GMVs at Time 1 and Time 2 in each ROI were associated with subsequent CBF changes (from Time 2 to Time 3), or if the CBF values at Time 2 in each ROI were associated with subsequent GMV changes (from Time 2 to Time 3).

MATERIALS AND METHODS

Study population

The CHS is a multicenter study established in 1989 to investigate risk factors for cardiovascular disease in elderly individuals. Between 1997 and 1999 (Time 1), the CHS-CS recruited non-AD participants at the University of Pittsburgh and only high-resolution structural MRIs were acquired for the participants. Between 2002 and 2003 (Time 2), 195 participants received both structural and perfusion MRIs. Neuropsychological assessments and Modified Mini-Mental State Examination (3MSE) were performed at both Time 1 and Time 2 [22-24]. The subjects were classified as NC, MCI, or AD yearly based on cognitive status adjudications [25] without verification of positive Aβ or positive tau. Therefore, AD should be viewed as probable AD herein. MCI, including MCI-amnestic and MCI-multiple cognitive domain types, was classified according to the CHS-CS diagnostic criteria [25]. The MCI amnestic type included subjects with impairments (defined as performance 1.5 SD below age/education appropriate means) in delayed recall of verbal or nonverbal material (or both) and with cognitive deficits that represented a decline from a previous level of functioning. Cognitive functions otherwise fell within normal limits. The diagnosis did not exclude individuals with mild alterations on instrumental activities of daily living (IADLs). Diagnosis of the second type, MCI–multiple cognitive deficits, required impairments in at least one cognitive domain other than memory (i.e., results of two or more tests were abnormal), or else one abnormal test result (which could be a memory test result) in at least two separate domains, without sufficient severity or loss of IADLs to constitute dementia. These cognitive deficits may or may not affect IADLs but must represent a decline from a previous level of functioning in order to fulfill the diagnostic criteria. Participants were classified with possible MCI when there were psychiatric, neurologic, or systemic conditions that could themselves cause cognitive deficits. Subjects were classified as having probable MCI when no comorbid factors were identified. A diagnosis of dementia was based on a deficit in performance in two or more cognitive domains that was of sufficient severity to affect IADLs, with a history of normal intellectual function before the onset of cognitive abnormalities. A memory deficit was not required for the diagnosis of dementia. The cognitive classification was interpolated based on the time of each MRI [26]. Prior inclusion and adjudication criteria were used [27].

The detailed summary for excluded subjects was previously listed [21]. Based on the exclusion criteria, 148 participants, including 58 NC subjects, 50 MCI patients, and 40 AD patients, had follow-up structural and ASL...
perfusion MRIs at Time 2 from 2002 to 2003. Between 2003 and 2009 (Time 3), Sixty-three of the 148 participants, including 15 stable-NC, 14 NC-to-MCI, 16 stable-MCI, and 18 MCI/AD-to-AD (9 MCI-to-AD, 9 stable-AD), had follow-up structural and perfusion MRIs (Fig. 1). Structural MRI and perfusion MRI occurred at the same MRI scanning session at either follow-up times (Time 2 or Time 3) for each subject. To obtain prior longitudinal data, we looked for MRI scans of the 63 subjects in 1997-1999. Forty out of the 63 participants, including 37 NC subjects and 3 MCI subjects, had structural MRIs (Time 1). No perfusion MRIs were performed in 1997-1999. Details of the longitudinal data at the three time points are listed in Figure 1.

Figure 1. Study schema. Sixty-three volunteers from the Cardiovascular Health Study (CHS) Cognition Study (CHS-CS) were used for this study. All of the volunteers received two sets of structural and perfusion MRIs during 2002-2009. The 63 included 40 volunteers from the University of Pittsburgh cohort of the CHS who also received neuropsychological assessment and structural MRIs during 1997-1999. None of the volunteers had AD when they were recruited for the CHS-CS.

**Image acquisition**

A GE Signa 1.5 T MRI (LX Version) at the University of Pittsburgh MR Research Center was used for all MRI scans. MRI images were acquired using a quadrature transceiver head coil. Written informed consent forms were approved by the institutional review board (IRB) and signed by all subjects or their caregivers. For high-resolution structural MRI, 3D T1-weighted spoiled gradient recalled echo (SPGR) structural images covering the whole brain were obtained (Voxel: 1x1x1.5 mm³, 5 ms echo time, 40° flip angle) [27, 28]. For perfusion MRI, labeling and acquisition sequences were multi-slice continuous arterial spin labeling (CASL) [27, 29, 30] and axial echo planar imaging (EPI). The MRI parameters were previously presented [30].

**Statistical analysis for demographic variables**

Forty out of 63 subjects had earlier structural scans at Time 1 in 1997-1999. We tested whether the 23 subjects without earlier structural scans had demographic (age, gender, education, hypertension, diabetes, and heart disease) differences from the 40 subjects with earlier structural scans at Time 1. The age of each subject at Time 1 was calculated based on his/her scanned or scheduled MRI date. All tests were 2-tailed and a p-value less than 0.05 was considered statistically significant. The Shapiro-Wilk test was used to assess normality of variables. Differences of each demographic variable were evaluated using two-sample t-tests or Mann-Whitney nonparametric U-tests for continuous variables, and χ² tests for categorical variables.

**Voxel-wise GMV analysis**

**Pre-processing**

Voxel-based morphometry (VBM) in SPM12 (Statistical Parametric Mapping) was used to register structural MRIs of different subjects to a common template through spatial normalization [31]. However, conventional VBM suffered from imperfect registration to the standard brain [32]. Diffeomorphic Anatomical Registration Through Exponentiated Lie (DARTEL) was introduced to allow for precise image registration [33]. DARTEL-based VBM was reported to provide a greater diagnostic accuracy in AD than conventional VBM methods [34]. Structural MRI data from 148 image sets at Time 2, 63 follow-up image sets at Time 3, and 40 image sets at Time 1 were spatially normalized with DARTEL-based VBM with SPM12 software. First, segmentation was performed to generate gray matter and white matter images in native space and DARTEL-imported space. Second, all gray matter and white matter images from the DARTEL-imported space were used to create group templates using iterative algorithms and the deformation fields from each subject’s native space into the Montreal Neurological Institute (MNI) template. Third, the deformation fields were applied to the corresponding gray matter images to output the GMV images in the standard MNI space for all of the subjects. The GMV images then have voxel-wise correspondence across subjects. Total GMV, total white matter volume (WMV), total cerebrospinal fluid (CSF)
volume, and total intracranial volume (TIV) for each subject were calculated using the SPM12 Util tool “Tissue Volumes” from the segmentation results.

**Statistical analysis**

The general linear models (GLMs) were employed to compare total GMVs, total WMVs, total CSF volumes, and TIVs from all of the subjects with the independent variables of NC, MCI, AD groups, and confounding variables of age and gender.

The GLM was also used to determine the voxels in GMV maps with significant differences between 58 NC, 50 MCI and 40 AD subjects (Time 2) using the Statistical Nonparametric Mapping (SnPM13) toolbox [35] within SPM12. The SnPM approach was adopted in the image statistical analyses because of the potentially increased family-wise error (FWE) rates from the SPM cluster-level analyses [36, 37]. The nonparametric approach was demonstrated to be robust using a FWE rate of 5% [37]. In the GLMs, the group index (MCI or AD) was considered as the covariate of interest and the age, gender, and TIV were considered as confounding variables (covariates of no interest). One thousand random permutations were performed. The cluster-forming threshold was defined using a voxel-wise threshold of p < 0.001. The largest supra-threshold cluster sizes from all 1000 permutations were used to calculate the empirical distribution in order to correct for multiple comparisons among voxels. Only the significant clusters with FWEs of 5% were reported.

Automatic anatomical labeling (AAL) for SPM12 was used for the anatomical labeling of each cluster [38]. The intersection of each cluster and the anatomical region of interest (aROI) was calculated as two percentages: the percentage of cluster (%Cluster) and the percentage of ROI (%Region). %Cluster was calculated as the ratio of the number of voxels in the intersection to that in the cluster. %Region was calculated as the ratio of the number of voxels in the intersection to that in the aROI.

**Region of interest (ROI) derived from GMV changes**

Clusters that showed significant GMV differences between NC and AD groups in the voxel-level analyses were considered as the atrophy ROI. Both left and right hippocampal ROIs were added as exploratory GMV ROIs because of frequently reported GMV loss in the hippocampus [13-15]. Because GMV atrophy was found in the left side from this study, the right hippocampal ROI was explored only if the left hippocampal ROI was not shown significant. The regional GMV for each ROI was calculated as the mean GMV over the region’s voxels.

**ROI derived from perfusion changes**

A perfusion ROI was derived using the voxel-wise analysis with the voxels in CBF maps with significant differences between 58 NC, 50 MCI and 40 AD subjects (Time 2) using SPM12 from our prior cross-sectional study [21]. Specifically, we extracted the temporoparietal region as the perfusion ROI. Its precise location and the method deriving it can be found in the Supplementary Material (Supplementary Fig. 1). The temporoparietal region was also chosen because it was consistently reported to have an early perfusion/metabolism decrease in AD across different imaging modalities: ASL perfusion MRI, SPECT, and PET glucose metabolism. Because GMV atrophy was found in the left side from this study, only the left temporoparietal region was used.

**Potential confounding factors of perfusion in the high-risk AD cohort**

AD patients with high genetic risk, i.e., those with the apolipoprotein E e4 (APOE4) allele in NC and MCI groups, have been shown with hyper-perfusion in the medial temporal lobes [39]. We therefore characterized the effect of APOE4 allele on brain perfusion in our high-risk AD cohort. For the 58 NC and 50 MCI participants at Time 2, 20 participants (12 NC, 8 MCI) carried the APOE4 allele (APOE+), including both homozygotes and heterozygotes; 73 participants (39 NC, 34 MCI) did not carry APOE4 allele (APOE-); 15 participants (7 NC, 8 MCI) did not have APOE tests. We compared perfusion maps and regional perfusion values in the left and right hippocampus regions between 20 APOE+ participants and 73 APOE- participants with age and gender as confounders. Additional comparisons were performed in the region-level analyses of hippocampus regions because the literature has reported hyper-perfusion in the hippocampus regions of APOE4 allele carriers [39] and regional analyses have increased signal-to-noise ratio (SNR) to detect the potential confounding factors. No significant perfusion difference was observed in the APOE4 carriers, indicating that the perfusion estimates in the high-risk AD cohort were not confounded by their APOE4 status.

**Relationship between GMVs (at Time 1 or Time 2) and longitudinal perfusion changes (from Time 2 to Time 3)**

Multiple linear regression models were created to investigate whether the regional GMVs (Time 2) were related to longitudinal regional perfusion changes (from Time 2 to Time 3). Longitudinal perfusion changes from the 63 subjects in each ROI were the dependent variables. GMV values from the 63 subjects in either ROI at Time 2
were the independent variables. Age, gender, and time gap between two perfusion scans were considered as covariates. Multiple linear regression models were also created for the subjects with AD progression (i.e., not stable NC) to investigate whether the relationship was sensitive to AD progression. We also applied the above two multiple linear regression models to investigate whether the regional GMVs at Time 1 in 1997-1999 were related to longitudinal regional perfusion changes (from Time 2 to Time 3) after 2002. Forty subjects were used in these additional analyses because only 40 out of the 63 subjects received structural MRIs in 1997-1999. Given the disproportionate AD prevalence between genders [40], the interaction of gender and independent variable (regional GMVs at Time 2 in this case) was assessed for all investigated associations.

**Relationship between perfusion at Time 2 and longitudinal GMV changes (from Time 2 to Time 3)**

Multiple linear regression models were created to investigate whether the regional perfusion values at Time 2 were related to longitudinal regional GMV changes (from Time 2 to Time 3). Longitudinal GMV changes from the 63 subjects in each ROI were the dependent variables. Regional perfusion values from the 63 subjects in either ROI at time 2 were the independent variables. Age, gender, and time gap between two structural MRI scans were considered as covariates. Multiple linear regression models were also performed for the subjects with AD progression (excluding those in the stable NC group). We cannot investigate whether the regional GM perfusion values at Time 1 in 1997-1999 are related to longitudinal regional GMV changes (from Time 2 to Time 3) after 2002 because no perfusion MRIs were acquired in 1997-1999.

**Relationship between longitudinal perfusion changes and longitudinal GMV changes (from Time 2 to Time 3)**

Multiple linear regression models were created to investigate whether the longitudinal perfusion changes were related to longitudinal regional GMV changes from Time 2 to Time 3. Longitudinal perfusion changes from the 63 subjects in each ROI were the dependent variables. Longitudinal GMV changes from the 63 subjects in either ROI were the independent variables. Age, gender, and time gap between two structural MRI scans were considered as covariates.

**RESULTS**

The demographic and cognitive information of the 148 subjects at Time 2 that were used to generate the GMV ROIs for abnormal GM atrophy in AD are listed in Supplementary Table 1 and reported in our previous publication [21]. No significant differences were observed for age, gender, and education between the three cognitive groups. Subjects with AD had lower 3MSE scores compared to NC and MCI subjects (p < 0.0001).

Table 1 summarizes the demographic and general cognitive information of the 63 subjects at two time points and 40 out of the 63 subjects at three time points. The 40 subjects had an average time gap of 5.4±0.6 years from Time 1 to Time 2 and of 2.3±1.6 years from Time 2 to Time 3. The 63 subjects had an average follow-up time of 2.3±1.7 years from Time 2 to Time 3. No significant differences were observed for age, gender, education, hypertension, diabetes, and heart disease between 40 subjects with Time 1 data and 23 subjects without Time 1 data.

**Comparison of global GMVs at Time 2**

We found an association of age with the four total brain volume measures (β = -0.42% per year, p = 0.0011 for the
total GMV; $\beta = -0.34\%$ per year, $p = 0.0042$ for the total WMV; $\beta = +0.31\%$ per year, $p = 0.042$ for the total CSF volume; $\beta = -0.46\%$ per year, $p = 0.079$ marginal for the TIV, respectively) and of gender (smaller in females) with the above four total brain volume measures ($\beta = -0.040$ liters, $p < 0.0001$; $\beta = -0.061$, $p < 0.0001$; $\beta = -0.078$ liters, $p < 0.0001$; $\beta = -0.18$ liters, $p < 0.0001$, respectively). However, no significant differences of total GMVs, total WMVs, total CSF volumes, and TIVs were observed between NC and MCI, between NC and AD, and between MCI and AD.

**Comparison of GMV maps at Time 2**

The AD subjects had decreased GMVs compared to NCs in the temporal pole region (Fig. 2A). No significant differences in GMVs were observed between the AD and MCI groups and between NC and MCI groups. In females, we also observed significantly larger GMVs in the rectus (Cluster 2), fusiform (Cluster 3), rolandic operculum and inferior frontal (Cluster 4), middle temporal (Cluster 5), precuneus and superior parietal (Cluster 6), and precentral (Cluster 7) regions after adjusting for age and TIV effects. Larger GMVs were associated with larger TIVs (C) after adjusting for age and gender effects. The color bars show the range of t-values.

**Correlation of GMVs (at Time 2) with longitudinal perfusion decline (from Time 2 to Time 3)**

For all of the subjects ($n = 63$), GMVs in the temporal pole region at Time 2 were significantly associated with longitudinal perfusion declines from Time 2 to Time 3 in this region (Fig. 3A, $p = 0.029$, $r = 0.28$) and in the temporoparietal region (Fig. 3C, $p = 0.0089$, $r = 0.33$), and the association remained significant only in the temporoparietal region after FWE correction. For the subjects with AD progression (i.e., not stable NC, $n = 48$), GMVs in the temporal pole region at Time 2 were
significantly associated with longitudinal perfusion declines from Time 2 to Time 3 in this region (Fig. 3B, $p = 0.0014, r = 0.46$) and in the temporoparietal region (Fig. 3D, $p = 0.0032, r = 0.43$), and both associations remained significant after FWE correction.

For our exploratory aim, left hippocampal GMVs at Time 2 were significantly associated with longitudinal perfusion declines in the temporoparietal region from Time 2 to Time 3 for all of the subjects (Supplementary Fig. 3A, $p = 0.027, r = 0.29$) and for the subjects with AD progression (Supplementary Fig. 3B, $p = 0.012, r = 0.37$). However, after FWE correction, this association remained significant only for the subjects with AD progression. More interestingly, the slopes for the subjects with AD progressions were larger than those derived using all of the subjects. However, the differences between the two slopes were not statistically significant.

For all of the subjects ($n = 63$), significant interaction between gender and temporoparietal GMV at Time 2 ($b = 2.76, p = 0.0052$) and marginally significant interaction between gender and hippocampal GMV at Time 2 ($b = 2.76, p = 0.0052$) were identified. These results suggest that gender may play a role in the progression of AD, with males experiencing greater GMV changes compared to females.

Figure 3. Correlation of longitudinal CBF changes from Time 2 to Time 3 in the temporoparietal region with GMV values at Time 2 after adjusting for age, gender, and time gap from Time 2 to Time 3. Longitudinal CBF changes in the temporoparietal region were significantly associated with (A) temporoparietal GMV values for all of the subjects ($n = 63$), (B) temporoparietal GMV values for the subjects with AD progression ($n = 48$), (C) temporal pole GMV values for all of the subjects ($n = 63$), and (D) temporal pole GMV values for the subjects with AD progression ($n = 48$).
interaction between gender and hippocampal GMV at Time 2 (b = 2.18, p = 0.088) were observed for longitudinal perfusion declines in the temporoparietal region. The association between the hippocampal GMV and temporoparietal CBF changes was significant in females (b = 1.93, p = 0.030) but not in males (b = 0.78, p = 0.50).

Table 2. Clusters with significantly decreased GMVs in the AD group relative to the NC group (Cluster 1) after adjusting for TIV, age, and gender; larger GMVs in females than males (Clusters 2-7) after adjusting for TIV and age; larger GMVs associated with larger TIVs (Clusters 8) after adjusting for age and gender.

<table>
<thead>
<tr>
<th>Cluster</th>
<th>N voxels</th>
<th>Peak-t</th>
<th>Peak-t MNI coordinates</th>
<th>Anatomical locations</th>
<th>%Cluster</th>
<th>%Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1178</td>
<td>4.08</td>
<td>-38, 12, -20</td>
<td>Temporal Lobe</td>
<td>29.56</td>
<td>17.28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Pole_Sup_L</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Mid_L</td>
<td>21.57</td>
<td>3.28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Sup_L</td>
<td>8.52</td>
<td>2.79</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Inf_L</td>
<td>8.26</td>
<td>1.94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Pole_Mid_L</td>
<td>3.20</td>
<td>3.18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Insula_L</td>
<td>11.58</td>
<td>4.68</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frontal Lobe</td>
<td>3.99</td>
<td>1.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frontal_Inf_Orb_L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1905</td>
<td>4.82</td>
<td>-2, 27, -28</td>
<td>Frontal Lobe</td>
<td>24.54</td>
<td>35.44</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rectus_R</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rectus_L</td>
<td>29.61</td>
<td>24.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frontal_Sup_Orb_R</td>
<td>6.88</td>
<td>7.42</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frontal_Sup_Orb_L</td>
<td>6.69</td>
<td>7.48</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Insula_R</td>
<td>0.37</td>
<td>1.38</td>
</tr>
<tr>
<td>3</td>
<td>1097</td>
<td>4.23</td>
<td>-36, -51, -15</td>
<td>Occipital Lobe</td>
<td>76.75</td>
<td>21.86</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fusiform_L</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occipital_Inf_L</td>
<td>6.83</td>
<td>4.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal Lobe</td>
<td>12.31</td>
<td>2.53</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Inf_L</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cerebelum</td>
<td>3.80</td>
<td>1.47</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cerebelum_6_L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1007</td>
<td>4.01</td>
<td>56, 12, 3</td>
<td>Frontal Lobe</td>
<td>36.67</td>
<td>14.65</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frontal_Inf_Oper_R</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rolandic_Oper_R</td>
<td>22.00</td>
<td>9.24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frontal_Inf_Tri_R</td>
<td>1.61</td>
<td>0.42</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal Lobe</td>
<td>14.67</td>
<td>6.13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Pole_Sup_R</td>
<td>7.69</td>
<td>1.37</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Sup_R</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Insula_L</td>
<td>11.27</td>
<td>3.56</td>
</tr>
<tr>
<td>5</td>
<td>1189</td>
<td>4.75</td>
<td>34, -69, 15</td>
<td>Temporal Lobe</td>
<td>40.51</td>
<td>6.83</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal_Mid_R</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occipital Lobe</td>
<td>17.65</td>
<td>6.24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occipital_Mid_R</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occipital_Sup_R</td>
<td>5.11</td>
<td>2.69</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cuneus_R</td>
<td>2.56</td>
<td>1.33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Parietal Lobe</td>
<td>3.50</td>
<td>0.80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Precuneus_R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1498</td>
<td>4.12</td>
<td>-26, -48, 66</td>
<td>Parietal Lobe</td>
<td>54.15</td>
<td>27.46</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Parietal_Sup_L</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Precuneus_L</td>
<td>28.56</td>
<td>8.47</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Precuneus_R</td>
<td>4.01</td>
<td>1.29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Postcentral_L</td>
<td>2.96</td>
<td>0.80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Parietal_Inf_L</td>
<td>1.91</td>
<td>0.82</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occipital Lobe</td>
<td>1.24</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cuneus_R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>1357</td>
<td>4.10</td>
<td>-38, -15, 66</td>
<td>Frontal Lobe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Aging and Disease • 8
## Regional cerebral blood flow and atrophy in AD

<table>
<thead>
<tr>
<th>8</th>
<th>Increased with TIV</th>
<th>226769</th>
<th>7.06</th>
<th>-2.27, -27</th>
<th>206769</th>
</tr>
</thead>
</table>
### Frontal Lobe
- **Precentral_L**: 80.03, 17.83
- **Frontal_Sup_L**: 9.16, 2.00
- **Frontal_Mid_L**: 2.82, 67.65
- **Frontal_Mid_R**: 2.55, 58.37
- **Frontal_Sup_R**: 2.21, 63.44
- **Frontal_Sup_L**: 1.70, 55.40
- **Precentral_L**: 1.70, 56.26
- **Frontal_Sup_Medial_L**: 1.59, 62.13
- **Frontal_Sup_Medial_R**: 1.14, 62.56
- **Supp_Motor_Area**: 1.14, 56.13
- **Frontal_Inf_Orb_L**: 1.00, 69.17
- **Frontal_Inf_Orb_R**: 0.93, 64.08
- **Frontal_Mid_Orb_R**: 0.76, 87.49
- **Rolandic_Oper_R**: 0.75, 66.49
- **Rectus_L**: 0.73, 100.00
- **Frontal_Sup_Orb_L**: 0.71, 86.91
- **Frontal_Med_Orb_R**: 0.71, 96.96
- **Frontal_Inf_Tri_R**: 0.69, 37.47
- **Frontal_Mid_Orb_L**: 0.68, 89.52
- **Supp_Motor_Area_L**: 0.68, 36.75
- **Frontal_Inf_Tri_L**: 0.66, 30.72
- **Rectus_R**: 0.64, 99.86
- **Frontal_Med_Orb_L**: 0.61, 98.75
- **Frontal_Sup_Orb_R**: 0.60, 70.71
- **Rolandic_Oper_L**: 0.47, 56.26
- **Frontal_Inf_Oper_R**: 0.44, 37.31
- **Precentral_R**: 0.39, 13.49
- **Olfactory_R**: 0.24, 98.27
- **Olfactory_L**: 0.23, 97.50
- **Frontal_Inf_Oper_L**: 0.15, 17.05

### Temporal Lobe
- **Temporal_Mid_R**: 2.56, 67.61
- **Temporal_Inf_R**: 2.46, 80.52
- **Temporal_Mid_L**: 2.01, 47.47
- **Temporal_Inf_L**: 1.70, 62.09
- **Temporal_Sup_L**: 1.24, 63.02
- **Temporal_Sup_R**: 1.20, 44.69
- **Temporal_Pole_Sup_R**: 0.63, 55.15
- **Temporal_Pole_Mid_R**: 0.50, 49.36
- **Temporal_Pole_Sup_L**: 0.26, 23.73
- **Amygdala_R**: 0.21, 99.19
- **Heschl_L**: 0.18, 94.22
- **Temporal_Pole_Mid_L**: 0.15, 23.31
- **Heschl_R**: 0.14, 65.46

### Occipital Lobe
- **Occipital_Mid_L**: 2.36, 84.25
- **Fusiform_R**: 1.77, 82.24
- **Calcarine_L**: 1.45, 75.24
- **Fusiform_L**: 1.37, 69.52
- **Occipital_Mid_R**: 1.35, 75.21
- **Calcarine_R**: 1.03, 64.53
- **Cuneus_L**: 1.01, 77.71
- **Lingual_R**: 1.00, 50.86
- **Cuneus_R**: 0.98, 80.89
- **Occipital_Sup_L**: 0.91, 78.33
- **Occipital_Sup_R**: 0.87, 72.18
- **Occipital_Inf_R**: 0.75, 89.28
- **Lingual_L**: 0.73, 41.09
- **Occipital_Inf_L**: 0.69, 85.97

### Parietal Lobe
- **Precuneus_R**: 2.24, 79.88
- **Precuneus_L**: 2.09, 68.99
- **Parietal_Sup_L**: 1.11, 62.95
- **SupraMarginal_R**: 1.07, 63.22
- **Angular_R**: 1.05, 70.37
Correlation of GMVs (at Time 1) with longitudinal perfusion decline from average 5.4 years later

For all of the 40 subjects, GMVs in the left temporoparietal region at Time 1 were significantly associated with its longitudinal perfusion declines from Time 2 to Time 3 (Fig. 4, p = 0.050, r = 0.33). However, after FWE correction, this association at Time 1 was no longer significant. GMVs in either the left hippocampus or the right hippocampus region were not associated with longitudinal perfusion declines from Time 2 to Time 3 in its region and in the temporoparietal region (p > 0.05). No significant interaction was observed between gender and left hippocampal GMV at Time 1 (p = 0.31) for all of the subjects.

Correlation of perfusion values at Time 2 with longitudinal GMV changes (from Time 2 to Time 3)

Perfusion values at Time 2 in the temporal pole region were marginally associated with its own longitudinal GMV changes (from Time 2 to Time 3) for all of the subjects (p = 0.079, r = 0.23) but significantly associated for the subjects with AD progression (Fig. 5A, p = 0.048, r = 0.30). Considering that there was not much cognitive progression in the stable-MCI group, we excluded the stable-MCI subjects to explore this association for the subjects with definite AD progression. After excluding...
the stable-MCI subjects, we found a significant association of perfusion values at Time 2 in the temporal pole region with its own longitudinal GMV changes for the subjects with definite AD progression (Fig. 5B, \( p = 0.011, r = 0.47 \)) and the association remained significant after FWE correction. Perfusion values in either hippocampus at Time 2 were not associated with longitudinal GMV changes (from Time 2 to Time 3) \( (p > 0.05) \). No significant interaction was observed between gender and temporal pole perfusion values at Time 2 \( (p = 0.98) \) for all of the subjects. Fig. 6 summarizes the correlation model derived among temporal pole CBF, temporoparietal CBF, temporal pole atrophy, and hippocampal atrophy.

![Graph showing correlation of longitudinal CBF changes from Time 2 to Time 3 with GMV values at Time 1 adjusted for age, gender, and time gap.](image)

**Correlation of longitudinal perfusion changes with longitudinal GMV changes (from Time 2 to Time 3)**

Longitudinal CBF changes in the temporal pole and left hippocampus were negatively associated with longitudinal changes of GMV values in the same regions (Supplementary Fig. 4A, \( p = 0.018, r = -0.30 \) for the temporal pole; Supplementary Fig. 4B, \( p = 0.027, r = -0.29 \) for the left hippocampus). However, after FWE correction, these associations lacked significance.

**DISCUSSION**

Our results showed that AD was associated with marked atrophy in the left temporal pole region. The atrophy in the temporal pole is consistent with the location of neuronal loss and neurofibrillary tangles in AD [41], the distribution of temporal lobe atrophy with advancing disease [42], and the progression of TDP-43 pathology in AD: stage 2 for atrophy in hippocampus and/or entorhinal cortex and stage 3 for extension to the anterior temporal pole cortex [43]. The left anterior temporal pole has also been associated with impairment of semantic memory in AD [44]. However, the observed temporal pole region finding is different from frequently reported early AD atrophic regions: hippocampal and entorhinal areas [45-48].

By contrast, using the 1997-1999 CHS-CS cohort, we observed significant hippocampal atrophy in AD in a prior publication [49]. It is worth noting that the current study used the 2002-2003 CHS-CS cohort data to derive the AD atrophic regions and therefore the current study has
subjects 4 to 5 year older than our prior study that used 1997-1999 data [49]. In addition, our prior 1997-1999 cohort used NCs who remained cognitively normal for at least 5 years after their MRI scans, while NCs from this cohort were considered as cognitively normal subjects at the time of their MRI scans. Therefore, there may not be a sharp boundary between NC and MCI groups as corroborated by no difference in the GMV between these two groups. We postulated that the observed atrophy in the temporal pole region reflects brain structural atrophy in a more advanced stage of AD compared to our prior 1997-1999 cohort.

We found that atrophy in the left temporal pole and left hippocampal regions at Time 2 was correlated with subsequent perfusion decline in the temporoparietal region. Our correlation results with longitudinal perfusion changes extend the prior cross-sectional study with an association between GMVs in the medial temporal cortex and perfusion values in the combined AD hypoperfusion area [20]. Despite no statistical significance, we observed a faster perfusion decline rate when the stable normal subjects were excluded. We also observed that atrophy in the left temporal pole at Time 2 was correlated with its own subsequent perfusion decline. Our results suggest that GMV in the temporal lobe is a strong indicator of future perfusion declines in the local and adjacent vessel territory. A faster rate of perfusion decline may occur as AD progresses. Brain atrophy in the temporal lobe can cause reduced demand for perfusion from the posterior cerebral artery (PCA). The temporoparietal region, located in the border zone of the PCA and middle cerebral artery (MCA), is very vulnerable to conditions such as small vessel diseases and impaired vessel autoregulation. Brain atrophy was shown to be predicted from the tau pathology [50]. These data support that the atrophy (and maybe tau) in the temporal lobe may be a major driver of hypoperfusion and highlight the potential relevance of temporal lobe atrophy to predict the progression of hypoperfusion in future clinical trials. Nevertheless, the negative association between GMV changes and CBF changes in the temporal pole and hippocampus regions (i.e., the larger GMV values declined, the higher CBF values increased) indicates strong perfusion compensation to save neuronal degeneration at the early stage of AD progression. The perfusion compensatory mechanism is supported by tau-induced abnormal angiogenesis with increased blood vessel density in animal models [51].

We also investigated the potential cause of atrophy in the temporal lobe. Longitudinal GMV changes from Time 2 to Time 3 were found to be associated with brain perfusion in the temporal pole region but not in the hippocampal region at Time 2. Failure to find the association between hippocampal perfusion and its atrophy may be caused by the cohort that we analyzed being in a relatively advanced stage and relative older age group as mentioned earlier. However, the initial hypoperfusion appearing in the hippocampus and entorhinal regions was supported by animal models. Capillary degeneration was shown to develop experimentally in the CA1 hippocampal sector and entorhinal cortex of rat brain and were associated with spatial memory deficits when chronic cerebral hypoperfusion was induced in aging animals for a year.
Our findings support the critically attained threshold of cerebral hypoperfusion (CATCH) hypothesis of Alzheimer’s pathogenesis [54]: advanced aging in the presence of a vascular risk factor can create a CATCH that distorts regional (temporal pole) brain microcirculation and impairs optimal energy metabolism to maintain healthy brain cell function.

In females, brain atrophy in the temporal pole and hippocampal regions was found to be associated with a faster perfusion decline in the temporoparietal region. A perfusion decline was an early event that heralds the decline of cognitive function in AD [8]. Therefore, our finding that females are more susceptible to the perfusion decline directly contributes to the understanding for the disproportionately higher prevalence of females with AD than males [40]. However, the increased prevalence of AD among women likely arises through a combination of factors, including sex hormones [55], brain structure [56], neuroinflammation [57], APOE genes [58], and life experiences [59]. More research is required to explain the increased risks of women in developing AD and tailor AD treatments to women.

Our results identified temporal dynamics between the decline of cerebral blood flow and brain atrophy (neurodegeneration) during AD progression, supporting the involvement of cerebrovascular pathology in AD. CBF reduction may emerge from reduced capillary densities [60, 61] and the prolonged vasoconstriction of brain blood vessels in AD [4, 62], which may be related to the leakage of neurotoxic products into the brain through a defective blood-brain barrier [63]. When CBF diminishes, damage to neurons (brain atrophy) occurs and brain cognitive functions corresponding to these neurons are compromised [64]. The temporoparietal and posterior cingulate cortex regions demonstrated both declined CBF and reduced glucose metabolism from the same AD cohort [9-12], suggesting the close link between CBF and glucose metabolism. Hypometabolism in the medial parietal and lateral temporoparietal regions is an AD biomarker of neurodegeneration [65]. Measurement of CBF in these regions with noninvasive means (e.g., ASL) may be a valuable option to investigate the vascular role in AD pathology.

This study has some limitations. First, the participants were classified into different groups based on adjudications of their cognitive status, not from biomarker-confirmed (i.e., A+/T+) diagnosis of AD [66]. Therefore, misclassification of AD patients may have occurred. Second, the CBF images were acquired using the 2D multi-slice CASL technique at 1.5T. The subsequent availability of PCASL, 3T MRI, and background suppressed 3D acquisitions have resulted in significant improvements in temporal SNR and potential sensitivity to CBF differences [67, 68]. Nevertheless, in this study, we were able to detect associations between atrophy and subsequent CBF decline, and between reduced CBF and subsequent atrophy using CASL. Third,

**Figure 6. Correlation model of relationship among temporal pole CBF, temporoparietal CBF, temporal pole atrophy, and hippocampal atrophy.** Path weights are partial correlation coefficients after adjusting for age, gender, and time gap for all of the subjects with AD progression (n = 48, excluding the stable NC subjects). The direction of arrows is from an early event to a later event. * Stands for partial correlation coefficients for all of the subjects with definite AD progression (n = 32, excluding the stable NC and stable MCI subjects).
history of structural central nervous system lesions, small vessel diseases, and stroke was excluded from the perfusion MRI study, despite individuals with a history of stroke having a 59% increased risk of developing AD [69]. Therefore, our findings cannot be extended to the broader population with vascular comorbidities. Further studies are needed to clarify whether vessel diseases and atrophy contribute independently to perfusion decline.

Our data suggested that hypoperfusion in the temporal pole region is associated with atrophy in this region and, subsequently, to perfusion declines in both the temporal pole region and temporoparietal region. We postulate that CBF reduction occurs as an early event, and the hippocampus and temporal lobe are generally more susceptible to hypoperfusion than other cortical regions [70]. However, we have not observed a direct association of hippocampal CBF and its atrophy because of missing CBF images in the Time 1 dataset. Future studies are warranted to study this crucial relationship.

In summary, hypoperfusion in the temporal pole preceding its atrophy suggests that hypoperfusion in the region may be an early event driving atrophy. Temporoparietal and temporal pole hypoperfusion follows atrophy in the temporal pole, indicating that the atrophy (and maybe tau) in the temporal pole may be a major driver of later hypoperfusion in the temporoparietal and temporal pole regions. The findings highlight the potential relevance of temporal lobe atrophy to predict the AD progression of hypoperfusion for future clinical trials.

Acknowledgments

This research was supported by contracts HHSN 26820120036C, HHSN26820080007C, HHSN268201 800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85 086, 75N92021D00006, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The research was also supported by the State University of New York at Binghamton, the Nevada Cancer Institute, the University of Pittsburgh, and Washington University in St. Louis. Dr. Weiying Dai was supported by the National Institute on Aging (NIA) R01AG066430, the National Institute of Mental Health (NIMH) R21MH126260, and the National Science Foundation (NSF) CMMI-2123061. Dr. Cyrus Raji was supported by the NIA RF1AG072637-01. Dr. Yulin Ge was supported by the National Institute of Neurological Disorders and Stroke (NINDS) R01NS108491 and RF1NS110041. Tony D. Zhou, a student from Vestal High School, Vestal, NY, USA, conducted his research under the guidance of Dr. H. Michael Gach.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health and National Science Foundation.

Conflict of Interest

The authors have no conflict of interest to report.

Supplementary Materials

The Supplementary data can be found online at: www.aginganddisease.org/EN/10.14336/AD.2023.0430.

References


Regional cerebral blood flow and atrophy in AD


